{"id":"NCT00574873","sponsor":"Pfizer","briefTitle":"Compare Bosutinib To Imatinib In Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive CML","officialTitle":"A PHASE 3 RANDOMIZED, OPEN-LABEL STUDY OF BOSUTINIB VERSUS IMATINIB IN SUBJECTS WITH NEWLY DIAGNOSED CHRONIC PHASE PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOGENOUS LEUKEMIA","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-02-05","primaryCompletion":"2010-08-31","completion":"2015-05-27","firstPosted":"2007-12-17","resultsPosted":"2012-11-05","lastUpdate":"2019-01-08"},"enrollment":502,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Chronic Myeloid Leukemia"],"interventions":[{"type":"DRUG","name":"Bosutinib","otherNames":["SKI 606"]},{"type":"DRUG","name":"imatinib","otherNames":["Gleevec"]}],"arms":[{"label":"1","type":"EXPERIMENTAL"},{"label":"2","type":"ACTIVE_COMPARATOR"}],"summary":"Two-arm, randomized, open-label trial designed to evaluate the efficacy and safety of bosutinib alone compared to imatinib alone in subjects newly diagnosed with chronic phase Chronic Myelogenous Leukemia (CML). The primary endpoint is cytogenetic response rate at one year.","primaryOutcome":{"measure":"Percentage of Participants With Complete Cytogenetic Response (CCyR) at Year 1","timeFrame":"Year 1 (48 weeks)","effectByArm":[{"arm":"Bosutinib","deltaMin":70,"sd":null},{"arm":"Imatinib","deltaMin":68.3,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.667"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":3},"locations":{"siteCount":165,"countries":["United States","Argentina","Belgium","Brazil","Canada","Chile","China","Colombia","France","Germany","Hong Kong","Hungary","India","Italy","Japan","Latvia","Lithuania","Mexico","Poland","Russia","Singapore","South Africa","South Korea","Spain","Taiwan","Thailand","Turkey (TÃ¼rkiye)","Ukraine","United Kingdom"]},"refs":{"pmids":["37553873","35235189","24944159","24919837","23116602","22949154","22825216"],"seeAlso":["https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=3160A4-3000&StudyName=Compare%20Bosutinib%20To%20Imatinib%20In%20Subjects%20With%20Newly%20Diagnosed%20Chronic%20Phase%20Philadelphia%20Chromosome%20Positive%20CML"]},"adverseEventsSummary":{"seriousAny":{"events":90,"n":248},"commonTop":["Diarrhoea","Nausea","Thrombocytopenia","Vomiting","Anaemia"]}}